{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:37:47Z","timestamp":1792715867653,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012576","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"publisher","award":["2025A1515011768"],"award-info":[{"award-number":["2025A1515011768"]}],"id":[{"id":"10.13039\/501100012576","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473445"],"award-info":[{"award-number":["82473445"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.esmoop.2026.108368","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:17:39Z","timestamp":1788895059000},"page":"108368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pseudoprogression in neoadjuvant immunotherapy for resectable NSCLC: a PET\u2013CT-based study"],"prefix":"10.1016","volume":"11","author":[{"given":"Y.","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3181-8465","authenticated-orcid":false,"given":"J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-4408","authenticated-orcid":false,"given":"L.-B.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-H.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-X.","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.-X.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.-J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Y.-L.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2026.108368_bib1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"9928","key":"10.1016\/j.esmoop.2026.108368_bib2","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data","volume":"383","year":"2014","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.esmoop.2026.108368_bib3","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108368_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108368_bib5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1056\/NEJMc2313778","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"390","author":"Horita","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108368_bib6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the Neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108368_bib7","first-page":"573","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"391","author":"Sorscher","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108368_bib8","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jtho.2018.12.011","article-title":"Pseudoprogression in non-small cell lung cancer upon immunotherapy: few drops in the ocean?","volume":"14","author":"Ferrara","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108368_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.esmoop.2026.108368_bib10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.esmoop.2026.108368_bib11","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108368_bib12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108368_bib13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.20892\/j.issn.2095-3941.2019.0144","article-title":"The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy","volume":"16","author":"Jia","year":"2019","journal-title":"Cancer Biol Med"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108368_bib14","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1007\/s00259-021-05610-x","article-title":"[18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma","volume":"49","author":"Vos","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"26","key":"10.1016\/j.esmoop.2026.108368_bib15","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1200\/JCO.24.00071","article-title":"Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer: a phase II multicenter study","volume":"42","author":"Blakely","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108368_bib16","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1038\/s41467-021-25188-0","article-title":"Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer","volume":"12","author":"Cascone","year":"2021","journal-title":"Nat Commun"},{"issue":"17","key":"10.1016\/j.esmoop.2026.108368_bib17","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1111\/1759-7714.14562","article-title":"Dynamic 18F-FDG PET\/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer","volume":"13","author":"Chen","year":"2022","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108368_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00259-017-3806-1","article-title":"Metabolic activity by 18F-FDG-PET\/CT is predictive of early response after nivolumab in previously treated NSCLC","volume":"45","author":"Kaira","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926023112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926023112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:41:16Z","timestamp":1792712476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926023112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2059702926023112"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108368","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pseudoprogression in neoadjuvant immunotherapy for resectable NSCLC: a PET\u2013CT-based study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108368"}}